Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on July 30, 2026, to announce its financial and operating results for the second quarter ended June 30, 2026. The key details of these results are provided in an accompanying press release (Exhibit 99.1), which is incorporated by reference into the filing. Investors should note that the information furnished in this Item 2.02 and Exhibit 99.1 is not considered 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, nor is it automatically incorporated into other SEC filings unless expressly stated. The primary focus of this 8-K is to disseminate the company's quarterly performance to the public.
Key Highlights
- 1Regeneron announced its Q2 2026 financial and operating results via a press release on July 30, 2026.
- 2The press release, furnished as Exhibit 99.1, contains the detailed results for the quarter ended June 30, 2026.
- 3This 8-K filing serves as the official notification of Regeneron's second-quarter performance.
- 4Investors are advised to review Exhibit 99.1 for specific financial metrics, revenue figures, and operational updates.
- 5The filing clarifies the 'furnished but not filed' status of the provided information under SEC regulations.
Frequently Asked Questions
The detailed financial and operating results for the quarter ended June 30, 2026, are available in the press release furnished as Exhibit 99.1 to this 8-K filing.
When information is 'furnished' under Item 2.02, it means the company is providing it to the SEC, but it does not carry the same legal implications as 'filed' information, such as liability under Section 18 of the Securities Exchange Act of 1934. It's primarily for public disclosure.
This 8-K filing itself does not list the specific financial figures. Those details are contained within the press release attached as Exhibit 99.1, which investors should consult for the exact Q2 2026 financial performance data.